Retina

This treatment is already approved for both diabetic macular edema (DME) and NIU-PS outside the US, including in 17 European countries.

The authors commented that the patient’s "age, relative acute onset, and lack of medical history make this an atypical presentation.”

Maria Vittoria Cicinelli, MD, Denise Loya-Garcia, MD, PhD, and Vishal Raval, MD, were announced as the recipients and will receive a $3,000 honorarium.

The award honors Ludwig von Sallmann, MD, a “distinguished international ophthalmologist and ophthalmic investigator whose contributions greatly increased the basic and clinical understanding of vision and ophthalmology.”

Tarcocimab is an investigational anti-VEGF therapy built on Kodiak's proprietary antibody biopolymer conjugate (ABC) platform.

Insights shed light on what the approval means for providers and their patients affected by this neurodegenerative retinal disease

ENCELTO is the first and only FDA-approved treatment for MacTel.

ENCELTO is the first and only FDA-approved treatment for MacTel.

Cortrophin Gel is a prescription medicine that is injected subcutaneously or intramuscularly indicated for severe acute and chronic allergic and inflammatory conditions affecting the eye.

The negative effects of smoking on ocular tissues are well known and include age-related macular degeneration (AMD), diabetic retinopathy, cataracts, contact lens-related keratitis, Graves’ ophthalmopathy ischemic optic neuropathy, and glaucoma.

The investigators set out to identify a correlation between the TyG index in CRAO in patients who had been newly diagnosed with the disease.

Researchers indicated that pediatric patients with Leber congenital amaurosis experienced improvements in vision.

The company announced it has successfully started imaging patients with its first prototype of its device using both near-infrared and green modes.

At the Envision Summit 2025 in San Juan, Puerto Rico, Kristen Nwanyanwu, MD, MBA, MHS, joined by her children, discussed her talk on eradicating TRD and the family-friendly environment of the conference.

At the Envision Summit 2025 in San Juan, Puerto Rico, retina program chairs Geeta Lalwani, MD, and Majda Hadziahmetovic, MD, discussed Hadziahmetovic's presentation on deep learning models of neovascular AMD as well as their time at the conference.

At the Envision Summit 2025 in San Juan, Puerto Rico, Mike Farkas, MD, discussed gene therapy research for retinal degenerations that sidetracks the current "status quo" therapies of AAV-based replacement and CRISPR-Cas9 genome editing.

Risk factors vary in both short-term and long-term periods following Boston Type 1 keratoprosthesis surgery.

Children experienced sudden vision loss, visual field constriction, nyctalopia and dyschromatopsia following febrile illness.

At the Envision Summit 2025 in San Juan, Puerto Rico, Kelly Donovan, MD, talked about her graduate research on the earliest phase of diabetic retinopathy, and trying to understand how hyperglycemia translates into disease.

At the Envision Summit 2025 in San Juan, Puerto Rico, Oleg Alekseev, MD, PhD, talked about difficulties in diagnosing inherited retinal degenerations due to mutations in over 300 different genes.

The UK-based company will debut the tool, called Dr.Noon CVD, at two conferences in March.

At the Envision Summit 2025 in San Juan, Puerto Rico, Ollya Fromal, MD, gave advice on how retina specialists can manage add-ons in their busy retina clinics.

At the Envision Summit 2025 in San Juan, Puerto Rico, Sharon Fekrat, MD, FACS, FASRS talked about multi-modal retinal and choroidal imaging to diagnose and identify neurodegenerative diseases using machine learning.

Shah discusses several studies from the IRIS registry and plans for a retina program at next year's event to address the growing interest in retina procedures and techniques.

Advancements in drug durability and patient care are closing treatment gaps.